



**Diego Kyburz**

**Contact**

Diego Kyburz

## Publications (11)

Ciurea A, Götschi A, Bräm R, Bürki K, Exer P, Andor M, Nissen M, Möller B, Hügler T, Rubbert-Roth A, Kyburz D, Distler O, Scherer A, Micheroli R. Early axial spondyloarthritis according to the ASAS consensus definition: characterisation of patients and effectiveness of a first TNF inhibitor in a large observational registry. *RMD Open* 2023; 9

Riek M, Scherer A, Möller B, Ciurea A, Von Mühlengen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. *Sci Rep* 2023; 13:17776.

Micheroli R, Kissling S, Bürki K, Möller B, Finckh A, Nissen M, Exer P, Bräm R, Kyburz D, Rubbert-Roth A, Andor M, Baraliakos X, de Hooge M, Distler O, Scherer A, Ciurea A. Anaemia is associated with higher disease activity in axial spondyloarthritis but is not an independent predictor of spinal radiographic progression: data from the Swiss Clinical Quality Management Registry. *Clin Rheumatol* 2023; 42:2377-2385.

Amstad A, Papagiannoulis E, Scherer A, Rubbert-Roth A, Finckh A, Mueller R, Dudler J, Möller B, Villiger P, Schulz M, Kyburz D. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. *Rheumatology (Oxford)* 2022; 62:89-97.

Gilbert B, Moeller B, Kyburz D, Rubbert-Roth A, Courvoisier D, Studer O, Trunk E, Lauper K, Mongin D, Lamacchia C, Finckh A. Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis. *BMJ Open* 2021; 11:e048409.

Ciurea A, Scherer A, Distler O, Kyburz D, Dan D, Müller A, Bräm R, Andor M, Rubbert-Roth A, Möller B, Micheroli R, von Loga I, Bürki K, Papagiannoulis E, Finckh A. Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. *Ann Rheum Dis* 2020; 80:238-241.

Walker U, Müller R, Jaeger V, Theiler R, Forster A, Dufner P, Ganz F, Kyburz D. Disease activity dynamics in rheumatoid arthritis: patients' self-assessment of disease activity via WebApp. *Rheumatology (Oxford)* 2017; 56:1707-1712.

Alpizar-Rodriguez D, Gabay C, Courvoisier D, Lamacchia C, Mahler M, Roux-Lombard P, Von Mühlengen I, Walker U, Kyburz D, Zufferey P, Ciurea A, Dudler J, Möller B, Müller R, Finckh A. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. *Rheumatology (Oxford)* 2017; 56:1579-1585.

Alpizar-Rodriguez D, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Mahler M, Zufferey P, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlengen I, Kyburz D, Finckh A. The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. *Clin Rheumatol* 2017

Boehncke W, Yawalkar N, Villiger P, Navarini A, Möller B, Michel B, Laffitte E, Kyburz D, Häusermann P, Hasler P, Hasler F, Dudler J, Conrad C, Anliker M, Gabay C. The dermatologists' role in managing psoriatic arthritis: results of a Swiss Delphi exercise intended to improve collaboration with rheumatologists. *Dermatology (Basel)* 2015; 230:75-81.

von Kempis J, Dudler J, Hasler P, Kyburz D, Tyndall A, Zufferey P, Villiger P. Use of abatacept in rheumatoid arthritis. *Swiss Med Wkly* 2012; 142:w13581.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)